Sphere Bio develops and manufactures single-cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, and cell therapy workflows, streamlining the journey of discovery in labs, globally.
Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of direct sales and support staff throughout the United States, Europe and experienced distribution channels across APAC.